Effect of therapeutic lifestyle change on metabolic syndrome in adults: a randomized controlled trial Authors: Gebremedhin Gebreegziabiher, Tefera Belachew, Dessalegn Tamiru Published: 2025 ABSTRACT Metabolic syndrome (MetS) is the co-occurrence of multiple cardio-metabolic risk factors, including central obesity, hyperglycemia, hypertension, and dyslipidemia. MetS doubles the risk of CVD and increases the risk of T2DM fivefold. Therapeutic lifestyle change (TLC) has been recommended as the primary intervention for MetS. This interventional study was aimed at assessing the effect of TLC on MetS and other metabolic components. A two-arm, double-blinded community-based RCT was used among MetS-positive adults. Participants were randomly assigned to either the intervention group (IG) (n = 75) or the control group (CG) (n = 75). Participants in the IG received a TLC program focused on dietary modification, exercise, and behavioral change. A booklet and biweekly counseling were given, containing comprehensive information on MetS and its management approach. The intervention was implemented for three months. Baseline and end line data were collected. ANCOVA and GEE tests were used for continuous and categorical outcome variables, respectively. TLC improved almost all of the metabolic risk factors simultaneously, including weight, WC, BMI, TC, FBG, TG, and SBP. On average over time, the IG has − 868 g, -1.65 cm, -0.36 kg/m2, -5.51 mg/dl, -4.83 mg/dl, -5.87 mg/dl, and − 4.76 mmHg lower mean weight, WC, BMI, TC, FBG, TG, and SBP, respectively. The mean number of MetS components was significantly decreased by -0.424 among the IG compared to the CG. Likewise, the prevalence of MetS significantly decreased to 58.9% (p < 0.001) and 84.7% (p = 0.001) among the IG and CG, respectively. On average over time, the odds for recovery from MetS in the IG were 3.9 (p = 0.001) times as high as the odds for recovery in the CG. The trial resulted in a significant reduction in MetS prevalence and the majority of the anthropometric and cardio-metabolic biomarkers. Ameliorating the metabolic risk factors by implementing TLC may decrease the costs of medical therapy, hospitalization, and chronic care.Trial registration: This study was registered in the Pan African Clinical Trials Registry (with a unique identification number of PACTR201909866468898) on 30 Sep 2019.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28451-2. Introduction Metabolic syndrome (MetS) is the co-occurrence of multiple cardio-metabolic risk factors, including central obesity, hyperglycemia, hypertension, and dyslipidemia1. Consistent with the global epidemic of overweight and obesity, MetS has been progressing, with a magnitude of 24.0% to 78.0% in western populations2,3. A quarter of adults worldwide have MetS4. It is an increasingly prevalent disorder characterized by a clustering of metabolic risk factors. Besides, it is a complex set of cardiovascular risk factors associated with abdominal fat accumulation and resistance to insulin1,5, with an estimated prevalence of 33% in the United States2. It doubles the risk of cardiovascular disease (CVD) and increases the risk of type 2 diabetes mellitus (T2DM) five-fold6. People with MetS have higher healthcare utilization costs when compared to people without MetS7. Likewise, MetS patients have higher outpatient attendance, longer inpatient stays, and higher medical costs3. Given its increasing magnitude, it has imposed a heavy burden on the health care system. Therefore, effective interventions are urgently needed for the MetS positive population. People with MetS are often physically inactive and have abdominal obesity. One effective management strategy for MetS is thought to be dietary modification and physical activity, with therapeutic guidelines promoting multi-factorial lifestyle changes as the primary treatment6. The main recommendations for MetS prevention and treatment are lifestyle change through a multi-factorial approach based on behavioral change, physical exercise, and a healthy diet, as well as pharmacological strategies8,9. Weight reduction has a positive impact on all the risk factors for MetS, and exercise improves energy balance, decreases insulin resistance, and improves physical fitness, which in turn reduces the risk of CVD10. Programs of lifestyle change that include nutritional education and supervised physical exercise were effective in achieving the proposed goals for the treatment of MetS11. Lifestyle intervention is effective in reducing MetS prevalence and the severity of its individual components. However, few studies use this approach in their interventional studies11–13. There were also some limitations in previous studies. Most of the studies were conducted in developed countries. Some of their interventions, e.g., computer-assisted education14, on-site exercise15, and provision of supplements16, may not be feasible or suitable to be applied in developing countries with limited resources and facilities. Only limited numbers of multi-factorial lifestyle interventions were performed, and some participants even had no MetS. Because of these limitations, it may be difficult for health service providers to make decisions regarding the implementation of multifaceted lifestyle interventions for people with MetS. Therefore, the aim of this interventional study was to test whether a multi-factorial therapeutic lifestyle intervention, compared to usual care, improves MetS, its components, and other cardio-metabolic risk factors. Methods Study area, design, and population A two-arm, double-blinded community-based randomized controlled trial (RCT) was used among 145 adult study participants in Mekelle City, Northern Ethiopia, from October to December, 2019. All adult individuals aged 40 to 64 years who had lived in the city for at least six months and were diagnosed with MetS during the screening were considered eligible for inclusion in the study. The diagnosis of MetS was established based on the International Diabetes Federation (IDF) criteria1, which define MetS as the presence of central obesity—indicated by a waist circumference (WC) of ≥ 94 cm for men or ≥ 80 cm for women—together with at least two of the following four metabolic abnormalities: elevated triglyceride (TG) levels ≥ 1.7 mmol/L (≥ 150 mg/dL), reduced high-density lipoprotein cholesterol (HDL-C) (< 1.03 mmol/L or < 40 mg/dL for men and < 1.3 mmol/L or < 50 mg/dL for women), raised blood pressure (systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg, or current use of anti-hypertensive medication), and elevated fasting blood glucose (FBG) (≥ 5.6 mmol/L or ≥ 100 mg/dL, or current use of diabetes medication). Accordingly, individuals meeting these criteria were enrolled as study participants. The following were considered exclusion criteria: absolute contraindication for physical activity due to known health problems; being pregnant or lactating women (first year); being on medication for MetS-related health problems (obesity, hypertension, dyslipidemia, and diabetes); individuals with major illnesses; and being involved in another physical activity program. Individuals with MetS, which require treatment, were also omitted from the study in order to be treated in accordance with the national guideline17. This study was registered in the Pan African Clinical Trials Registry on 19/09/2019 (with a unique identification number of PACTR201909866468898). Sample size determination and sampling technique The primary outcomes of this interventional study were the five components of MetS and other related CVD risk factors (body weight, body mass index (BMI), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C)). The presence or absence of MetS was considered the secondary outcome variable. Sample size has been calculated using the secondary outcome variable (metabolic syndrome) using a formula recommended for dichotomous outcome variable18, . The findings of a clinical trial conducted in South Korea was used to calculate the sample size. The finding was that, at the end of a three-month lifestyle intervention, the prevalence of MetS in the intervention group was 45.5%, whereas it was 69.7% in the control group19. After adding 15% of the calculated sample size for lost follow-up (dropout rate), 65.4 + 9.8 = 75.2 = ~ 75. The final sample size for each group was 75. The total sample size was 150. Adults with MetS were recruited using IDF criteria. Anthropometry, mainly WC, was measured during the screening to confirm central obesity (it is advised to utilize the IDF cut-off point for Europeans, which is WC of 94 cm for males and 80 cm for females)1 before proceeding to the next stage. Once the WC was fulfilled, the individuals were checked for the remaining four MetS parameters (blood pressure, FBG, HDL-C, and TG). To collect fasting blood samples, the participants were asked for voluntary participation, and if they agreed to participate, an appointment was given for the next morning. In addition to the WC, if two of the four MetS components satisfy the IDF criteria, they were classified as having MetS and this process was continued until the sample size was fulfilled. People with MetS who need pharmacologic treatment were excluded from the study to get care in accordance with the national guideline17. They were linked to their preferred health facility with their results. After fulfilling the required sample size (n = 150), they were randomly assigned to the two study arms, including an IG called therapeutic lifestyle change (TLC) and a CG (usual care) by lottery method. Computer-generated random numbers were used to generate the allocation sequence. Sequentially numbered, opaque, and sealed envelopes were used to conceal the sequence until interventions were assigned. The investigators were responsible to generate the allocation sequence, enroll, and assign participants to study arms. Trial participants, nutrition counselors, and outcome assessors were blinded to the intervention assignment. The total sample size was stratified by sex2 and the number of MetS components (3 = 3, 4, and 5) prior to randomization (Table 1, CONSORT checklist). Table 1Stratification using sex and number of MetS components (n = 145).Stratifying variablesBaselineEnd lineCategoryUsual careTLCCategoryUsual careTLCSexMale (58)2929M (55)2629Female (92)4646F (90)4644Number of MetS components3 (91)45463 (88)42464 (51)26254 (49)26235 (8)445 (8)44 Total 75 75 72 73 Table 1Stratification using sex and number of MetS components (n = 145).Stratifying variablesBaselineEnd lineCategoryUsual careTLCCategoryUsual careTLCSexMale (58)2929M (55)2629Female (92)4646F (90)4644Number of MetS components3 (91)45463 (88)42464 (51)26254 (49)26235 (8)445 (8)44 Total 75 75 72 73 Stratification using sex and number of MetS components (n = 145). Baseline measures Before proceeding to an intervention, baseline data were collected from all individuals included in the follow-up study, and they were followed for 3 months. The socio-demographic information was collected at baseline through a semi-structured questionnaire. In addition, smoking habits, alcohol consumption, physical activity, biochemical, and anthropometric data were collected using the WHO STEEPs survey questionnaire20. The interview covered food consumption patterns using the 24-h dietary recall method and the food frequency questionnaire (FFQ) (supplementary file), with self-reported food intake and portion size. The estimation of portion size was facilitated by the use of measurement aids (standard household measures). To estimate the energy and nutrient intakes, the estimated portion size or amount of food intake was multiplied by the values of nutrient and energy content in foods as found in the food composition tables or databases21. The level of FBG was measured using a hexokinase enzymatic method, and the serum lipid levels were assessed enzymatically with commercially available reagents at the Tigray Health Research Institute. Anthropometric measurements were conducted while participants were wearing lightweight clothing and without shoes. Height was measured without shoes to the nearest 0.1 cm by using a stadiometer, and weight was measured using a digital scale to the nearest 0.1 kg. WC was measured to the nearest 0.1 cm by placing a non-stretching measuring tape horizontally around the participant’s abdomen midway between the lowest (12th ) rib and iliac crest when the participant exhaled completely. Hip circumference was measured at the largest part of the hip using non-stretching measuring tape. All anthropometric measurements were conducted in triplicate, and mean values were used in the analyses. Blood pressure was measured in triplicate using a WHO Microlife BP 3AC1 automated (oscillometric) digital sphygmomanometer measuring device after being properly sited and taking adequate rest for five minutes, and the mean value was used. Intervention An Intervention Study Team (IST) was established to ensure proper implementation and monitoring of the intervention. The team comprised four health professionals: one public health professional, two nutritionists, and one laboratory technologist. Prior to the commencement of the intervention, the team received a five-day intensive training focused on the intervention protocol, data collection, counseling techniques, and monitoring procedures. The IST was responsible for implementing the TLC program among participants in the IG. The intervention was based on the TLC program recommended by the IDF1 and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)8 guidelines. It integrated three major components: dietary modification, physical activity, and behavioral modification strategies. Participants were advised to stop smoking, stop or limit alcohol consumption, reduce total fat intake (especially saturated), avoid trans fats, limit salt intake to below 5 g per day, avoid refined sugars and sugary beverages, and maintain an active lifestyle while avoiding sedentary behavior. As part of lifestyle therapy for MetS, participants were counseled to maintain a healthy body weight by balancing calorie intake with regular physical activity. Overweight individuals were encouraged to aim for gradual weight loss of 5–10% to help improve blood pressure, blood glucose, and lipid profiles. The dietary advice emphasized consumption of high-fiber, complex carbohydrates such as whole grains, legumes, fruits, and vegetables; healthy fats from sources like sunflower oil, safflower oil, nuts, seeds, and fatty fish; and lean protein sources including fish, poultry, and legumes. Participants were advised to avoid trans fats, processed foods, and sugar. They were also encouraged to eat a variety of fruits and vegetables daily and to avoid or moderate alcohol consumption. The IST supported each participant in the IG by helping them set personalized goals based on their specific MetS components and challenges. Individualized counseling sessions were provided biweekly (every two weeks) for a total of six rounds, each lasting approximately one hour. Counseling was delivered by nutritionists and public health professionals using the Triple A cycle—Assessment, Analysis, and Action—at each visit. During these sessions, participants reviewed progress toward previously set goals, discussed challenges and strategies for overcoming barriers, set new dietary and physical activity goals, and received constructive feedback and encouragement for their achievements. A food and activity diary was used to facilitate self-monitoring of diet, body weight, waist circumference, and exercise adherence. In addition, participants received a booklet containing practical information on nutrition, physical activity, and behavior change. According to the WHO guideline22, adults aged 18–64 years should engage in at least 150 min of moderate-intensity aerobic physical activity per week, distributed throughout the week. Moderate-intensity activities are those that elevate heart rate and breathing but still allow conversation (the “talk test”), corresponding to 50–70% of maximum heart rate (HRmax) or 3.0–5.9 METs, where HRmax = 220 − age. Participants were encouraged to perform aerobic exercises such as brisk walking, cycling, or dancing to enhance insulin sensitivity, body composition, and blood pressure. The program targeted 25 min per day during weekends and 20 min per day during weekdays, adjusted according to individual capacity and WHO recommendations. Exercise intensity was monitored using heart rate or perceived exertion to ensure moderate but sustainable effort. At baseline and during follow-up, participants underwent individual assessments including body weight, waist circumference, dietary habits, physical activity levels, and readiness to change. These assessments guided the personalization of dietary and activity recommendations. Motivational strategies included discussing personalized health risks, emphasizing the benefits of modest weight loss, and providing moral support and positive reinforcement. Progress was continuously monitored through 24-hour dietary recalls, FFQ, and review of diaries. Barriers to adherence were discussed, and action plans were revised accordingly. Lack of progress was addressed through supportive, non-critical counseling to encourage persistence. Overall, the lifestyle intervention was a comprehensive and personalized program targeting modifiable cardiovascular risk factors associated with MetS. It aimed to achieve and maintain healthy body weight, dietary patterns, and physical activity behaviors through structured counseling, education, and motivational support, thereby improving overall metabolic health outcomes. Participants in the CG were linked to their nearest health facility to receive the usual care provided in health facilities, which may include routine counseling and general health advice from healthcare providers without the structured TLC program. Motivation and compliance Dietary, physical activity, and behavioral counseling interventions were implemented biweekly (every two weeks). Attendance for each lifestyle counseling session was tracked using participants’ unique code numbers. Adherence to dietary and physical activity recommendations was assessed every two weeks using self-reported data collected through structured questionnaires. Participants were provided with a diary to record their daily activities, including the type, duration, and amount of exercise performed, as well as their dietary intake. For the dietary component, participants were asked to report the types and quantities of foods consumed using a 24-hour dietary recall and a FFQ. They were also asked whether they had followed their prescribed dietary plan. The FFQ was used to evaluate overall dietary habits during the two weeks preceding each counseling session. Compliance with the intervention was closely monitored over the three-month period, and participants maintained detailed records in their diaries. Adherence and compliance were reviewed and assessed at each follow-up visit. Physical activity levels were assessed using the International Physical Activity Questionnaire – Short Form (IPAQ-SF)23, while dietary behaviors were evaluated using a modified version of the WHO STEPS questionnaire20. Outcome measures Anthropometric measurement After three months of follow-up, all post-intervention data were collected from both the IG and CG. The primary outcomes included anthropometric changes, alterations in the five components of MetS, and changes in the overall prevalence of MetS. Anthropometric measurements—body weight, WC, and BMI—were assessed at baseline and at the end of the follow-up period. Comparisons were conducted within the IG (baseline versus post-intervention), within the CG (baseline versus post-intervention), and between the two groups to evaluate the differential effects of the intervention. Biochemical test Fasting blood samples were collected in the early morning after an overnight fast using test tubes containing a glycolytic inhibitor. The samples were immediately placed in ice water and processed promptly to separate plasma. The separated plasma was then stored in a deep freezer at − 70 °C until analysis. FBG, HDL-C, TG, TC, and LDL-C were analyzed using an automated chemistry analyzer (Bio-System A25, Spain) at the Tigray Health Research Institute. All laboratory analyses were performed by a qualified laboratory technologist who was blinded to the participants’ group assignments. FBG test was performed using the glucokinase method on the automated chemistry analyzer machine, while lipid profile measurements were conducted enzymatically at both baseline and post-intervention. Definition of terms MetS was defined as the presence of an elevated WC of ≥ 94 cm for men and ≥ 80 cm for women, plus at least two of the following four components: elevated TG (≥ 150 mg/dL); reduced HDL-C < 1.03 mmol/L (< 40 mg/dL) for men and < 1.3 mmol/L (< 50 mg/dL) for women; elevated blood pressure (≥ 130/85 mmHg) or current use of anti-hypertensive medication; and elevated FBG ≥ 5.56 mmol/L (≥ 100 mg/dL) or current use of diabetes medication1. BMI was calculated by dividing body weight (in kilograms) by height squared (in meters). Participants were categorized as underweight (BMI < 18.5 kg/m²), normal (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), or obese (≥ 30.0 kg/m²)24. An abnormal lipid profile was defined based on the presence of one or more of the following abnormalities: elevated TC ≥ 5.17 mmol/L (≥ 200 mg/dL); elevated LDL-C ≥ 3.36 mmol/L (≥ 130 mg/dL); reduced HDL-C < 1.03 mmol/L (< 40 mg/dL) for men or < 1.3 mmol/L (< 50 mg/dL) for women; and elevated TG ≥ 1.7 mmol/L (≥ 150 mg/dL)8. Data management and analysis Data were coded and entered into Epi-Data version 3.1 and subsequently exported to SPSS version 24 for final analysis. To ensure data quality, double data entry and range checks for data values were performed, and the dataset was thoroughly cleaned prior to analysis. The study followed a per-protocol (complete-case) analysis approach. Effect sizes for continuous variables were calculated as the mean change from baseline. For continuous outcome variables, beta coefficients were used, while odds ratio was used for categorical outcome variable. Continuous variables with normal distributions were summarized as mean ± standard deviation (SD). Baseline differences between the IG and CG were assessed using an independent samples t-test, while paired t-tests were used to examine within-group changes from baseline to post-intervention. The chi-square test was applied to assess differences in categorical outcome variables both within and between study arms. For continuous outcome variables, an analysis of covariance (ANCOVA) was conducted. This analysis adjusted for baseline differences, and results were reported as adjusted mean ± SD differences. In addition, partial eta-squared values were presented to indicate the proportion of variation in outcome variables attributable to the intervention. For the categorical outcome variable (presence of MetS), a generalized estimating equation (GEE) model was used, and result was expressed as odds ratio with 95% confidence interval. Statistical significance was set at p < 0.05 for all analyses. Results Baseline characteristics of the participants A total of 150 participants (58 men and 92 women) were recruited and enrolled in the trial. Overall, 96.7% of participants completed the study, with three men and two women withdrawn. Participant attrition was comparable between groups, with two participants dropped out from the IG and three from the control group CG. More than two-thirds of participants in both groups were married. The mean age of the CG was slightly higher than that of the IG, although the difference was not statistically significant (p = 0.285). Approximately one-third and over one-quarter of participants in both groups had completed secondary and tertiary education, respectively. Only a small proportion of participants were smokers—1.4% in the CG and 4.1% in the IG. Similarly, alcohol consumption was reported by more than two-thirds of the CG and about three-quarters of the IG. The majority of participants in both groups reported moderate levels of physical activity. The mean daily sitting time was slightly higher in the IG, with a non-significant difference between groups (p = 0.426) (Table 2). Table 2Background characteristics of the participants (n = 145).VariablesCategoriesCG, n = 72IG, n = 73X2/t-test (p-value)Sex, n(%)Male26 (47.3)29 (52.7)0.201 (0.654)Female46 (51.1)44 (48.9)Age, mean (SD)48.81 (7.27)47.58 (6.52)1.073 (0.285)¶Marital status, n(%)Single4 (5.6)10 (13.7)4.970 (0.290)Married50 (69.4)53 (72.6)Separated6 (8.3)3 (4.1)Divorced5 (6.9)3 (4.1)Widowed7 (9.7)4 (5.5)Educational status, n(%)Unable to read/write11 (15.3)8 (11.0)1.090 (0.780)Primary16 (22.2)20 (27.4)Secondary25 (34.7)23 (31.5)Tertiary20 (27.8)22 (30.1Occupation, n (%)Government employee7 (9.7)12 (16.4)2.925 (0.712)Private sector employee5 (6.9)8 (11.0)Merchant22 (30.6)20 (27.4)Housewife24 (33.3)21 (28.8)Daily laborer2 (2.8)3 (4.1)Others12 (16.7)9 (12.3)Monthly income, mean (SD)7309.72 (4726.59)7632.33 (5446.69)0.381 (0.704)¶Smoking status, n (%)Yes1 (1.4)3 (4.1)0.620 (0.315)No71 (98.6)70 (95.9)Alcohol consumption, n (%)Yes50 (69.4)54 (74.0)0.366 (0.545)No22 (30.6)19 (26.0)Level of activity, n (%)Low4 (5.6)5 (6.8)2.654 (0.265)Moderate57 (79.2)63 (86.3)Vigorous11 (15.3)5 (6.8)Sitting time per day in hours, mean (SD)3.69 (1.98)3.97 (2.10)0.799 (0.426)¶¶t-test; CG: control group, IG: intervention group. Table 2Background characteristics of the participants (n = 145).VariablesCategoriesCG, n = 72IG, n = 73X2/t-test (p-value)Sex, n(%)Male26 (47.3)29 (52.7)0.201 (0.654)Female46 (51.1)44 (48.9)Age, mean (SD)48.81 (7.27)47.58 (6.52)1.073 (0.285)¶Marital status, n(%)Single4 (5.6)10 (13.7)4.970 (0.290)Married50 (69.4)53 (72.6)Separated6 (8.3)3 (4.1)Divorced5 (6.9)3 (4.1)Widowed7 (9.7)4 (5.5)Educational status, n(%)Unable to read/write11 (15.3)8 (11.0)1.090 (0.780)Primary16 (22.2)20 (27.4)Secondary25 (34.7)23 (31.5)Tertiary20 (27.8)22 (30.1Occupation, n (%)Government employee7 (9.7)12 (16.4)2.925 (0.712)Private sector employee5 (6.9)8 (11.0)Merchant22 (30.6)20 (27.4)Housewife24 (33.3)21 (28.8)Daily laborer2 (2.8)3 (4.1)Others12 (16.7)9 (12.3)Monthly income, mean (SD)7309.72 (4726.59)7632.33 (5446.69)0.381 (0.704)¶Smoking status, n (%)Yes1 (1.4)3 (4.1)0.620 (0.315)No71 (98.6)70 (95.9)Alcohol consumption, n (%)Yes50 (69.4)54 (74.0)0.366 (0.545)No22 (30.6)19 (26.0)Level of activity, n (%)Low4 (5.6)5 (6.8)2.654 (0.265)Moderate57 (79.2)63 (86.3)Vigorous11 (15.3)5 (6.8)Sitting time per day in hours, mean (SD)3.69 (1.98)3.97 (2.10)0.799 (0.426)¶¶t-test; CG: control group, IG: intervention group. Background characteristics of the participants (n = 145). ¶t-test; CG: control group, IG: intervention group. Effect of TLC on metabolic syndrome In both groups, the proportion of participants with MetS fell significantly by 41.1% (p 0.001) and 15.3% (p = 0.001) in the IG and CG, respectively. The prevalence of MetS among the IG and CG was, thus, 58.9% and 84.7%, respectively, at the completion of the intervention. The results of the logistic GEE analysis showed that, on average over time, the odds of recovery from MetS in the IG was 3.9 times higher than the odds of recovery in the CG (OR: 3.869, 95% CI: 1.750, 8.554, p = 0.001) (Table 3). Table 3Descriptive statistics and GEE analysis results of MetS (n = 145).VariablesControl ArmChi-square (p-value)Intervention ArmChi-square (p-value)BaselineFollow upBaselineFollow upMetabolic syndromeNegative,n (%)0 (0.0)11 (15.3)11.910 (0.001)*0 (0.0)30 (41.1)37.759 (< 0.001)*Positive, n (%)72 (100.0)61 (84.7)73 (100.0)43 (58.9)MetS negativeOR (95% CI)13.87 (1.75, 8.55)0.001* Table 3Descriptive statistics and GEE analysis results of MetS (n = 145).VariablesControl ArmChi-square (p-value)Intervention ArmChi-square (p-value)BaselineFollow upBaselineFollow upMetabolic syndromeNegative,n (%)0 (0.0)11 (15.3)11.910 (0.001)*0 (0.0)30 (41.1)37.759 (< 0.001)*Positive, n (%)72 (100.0)61 (84.7)73 (100.0)43 (58.9)MetS negativeOR (95% CI)13.87 (1.75, 8.55)0.001* Descriptive statistics and GEE analysis results of MetS (n = 145). Effect of TLC on components of MetS Descriptive statistics with paired t-test In the CG, the paired t-test for all variables showed a non-statistically significant difference from baseline except for BMI and FBG, for which the mean scores were increased by 0.14 kg/m2 (0.14 (0.01, 0.27), p = 0.041) and 2.02 mg/dl (2.02 (0.62, 3.42), p = 0.005), respectively. All anthropometric indicators were significantly decreased from baseline among the IG, with a mean reduction of -0.56 kg (-0.56 (-0.92, -0.19), p = 0.003), -1.25 cm (-1.25 (-1.83, -0.66), p < 0.001), and − 0.22 kg/m2 (-0.22 (-0.08, -3.08), p = 0.003) for body weight, WC, and BMI, respectively. FBG was significantly decreased by -3.14 mg/dl; LDL-C by -2.02 mg/dl, and SBP by -3.00 mmHg among the IG from baseline. The mean number of MetS components was also significantly reduced in both groups from baseline, with a mean change of -0.60 ((-0.81, -0.40), p < 0.001) and − 0.19 ((-0.37, -0.02), p = 0.034) among the IG and CG, respectively (Table 4; Fig. 1). Table 4Changes from baseline in the anthropometric and biochemical parameters in the CG and IG using the paired t-test (mean ± SD) (n = 145).VariablesCG, n=72IG, n=73Baseline, Mean (SD)Follow upMean (SD)Mean difference (95% CI)t-value (p-value)BaselineMean (SD)Follow upMean (SD)Mean difference (95% CI)t-value (p-value)Weight 73.62 (12.89)73.94 (12.60)0.32 (-0.02,0.66)1.907 (0.061)74.49 (10.78)73.93 (11.03)-0.56 (-0.92,-0.19)-3.051 (0.003)*WC97.8 (9.05)98.2 (8.59)0.40 (-0.19,0.99)1.365 (0.177)97.9 (7.49)96.7 (8.05)-1.25 (-1.83,-0.66)-4.262 (<0.001)*BMI28.66 (4.47)28.80 (4.42)0.14 (0.01,0.27)2.086 (0.041)*28.00 (3.63)27.79 (3.71)-0.22 (-0.08,-3.08)-3.084 (0.003)*TC194.9 (30.12)196.4 (30.27)1.51 (-1.55,4.56)0.984 (0.328)192.8 (33.02)189.1 (31.11)-3.71 (-7.52,0.11)-1.938 (0.057)FBG98.3 (15.05)100.3 (14.35)2.02 (0.62,3.42)2.870 (0.005)*99.5 (15.60)96.3 (12.48)-3.14 (-5.58,-0.70)-2.564 (0.012)*TG174.8 (43.03)177.1 (44.36)2.29 (-1.84,6.42)1.107 (0.272)174.8 (49.33)171.2 (45.61)-3.57 (-7.85,0.70)-1.665 (0.100)HDL-C53.9 (10.47)53.0 (10.50)-0.90 (-2.60,0.80)-1.058 (0.294)53.0 (9.80)54.3 (10.69)1.26 (-0.23,2.74)1.690 (0.095)LDL-C157.2 (46.78)158.3 (48.19)1.05 (-1.68,3.78)0.767 (0.446)156.0 (44.83)154.0 (42.03)-2.02 (-3.99,-0.06)-2.050 (0.044)*SBP131.6 (5.27)133.0 (10.67)1.35 (-0.92,3.61)1.185 (0.240)130.5 (6.13)127.5 (7.32)-3.00 (-4.78,-1.22)-3.354 (0.001)*DBP85.0 (3.80)85.7 (6.47)0.67 (-1.04,2.37)0.779 (0.438)84.8 (3.61)84.1 (4.53)-0.70 (-1.61,0.21)-1.526 (0.131)MetS comp3.47 (0.60)3.28 (0.83)-0.194 (-0.374,-0.015)-2.164 (0.034)*3.42 (0.60)2.82 (0.96)-0.603 (-0.808,-0.398)-5.867 (<0.001)*CG: control group, IG: intervention group, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure*Significant association. Table 4Changes from baseline in the anthropometric and biochemical parameters in the CG and IG using the paired t-test (mean ± SD) (n = 145).VariablesCG, n=72IG, n=73Baseline, Mean (SD)Follow upMean (SD)Mean difference (95% CI)t-value (p-value)BaselineMean (SD)Follow upMean (SD)Mean difference (95% CI)t-value (p-value)Weight 73.62 (12.89)73.94 (12.60)0.32 (-0.02,0.66)1.907 (0.061)74.49 (10.78)73.93 (11.03)-0.56 (-0.92,-0.19)-3.051 (0.003)*WC97.8 (9.05)98.2 (8.59)0.40 (-0.19,0.99)1.365 (0.177)97.9 (7.49)96.7 (8.05)-1.25 (-1.83,-0.66)-4.262 (<0.001)*BMI28.66 (4.47)28.80 (4.42)0.14 (0.01,0.27)2.086 (0.041)*28.00 (3.63)27.79 (3.71)-0.22 (-0.08,-3.08)-3.084 (0.003)*TC194.9 (30.12)196.4 (30.27)1.51 (-1.55,4.56)0.984 (0.328)192.8 (33.02)189.1 (31.11)-3.71 (-7.52,0.11)-1.938 (0.057)FBG98.3 (15.05)100.3 (14.35)2.02 (0.62,3.42)2.870 (0.005)*99.5 (15.60)96.3 (12.48)-3.14 (-5.58,-0.70)-2.564 (0.012)*TG174.8 (43.03)177.1 (44.36)2.29 (-1.84,6.42)1.107 (0.272)174.8 (49.33)171.2 (45.61)-3.57 (-7.85,0.70)-1.665 (0.100)HDL-C53.9 (10.47)53.0 (10.50)-0.90 (-2.60,0.80)-1.058 (0.294)53.0 (9.80)54.3 (10.69)1.26 (-0.23,2.74)1.690 (0.095)LDL-C157.2 (46.78)158.3 (48.19)1.05 (-1.68,3.78)0.767 (0.446)156.0 (44.83)154.0 (42.03)-2.02 (-3.99,-0.06)-2.050 (0.044)*SBP131.6 (5.27)133.0 (10.67)1.35 (-0.92,3.61)1.185 (0.240)130.5 (6.13)127.5 (7.32)-3.00 (-4.78,-1.22)-3.354 (0.001)*DBP85.0 (3.80)85.7 (6.47)0.67 (-1.04,2.37)0.779 (0.438)84.8 (3.61)84.1 (4.53)-0.70 (-1.61,0.21)-1.526 (0.131)MetS comp3.47 (0.60)3.28 (0.83)-0.194 (-0.374,-0.015)-2.164 (0.034)*3.42 (0.60)2.82 (0.96)-0.603 (-0.808,-0.398)-5.867 (<0.001)*CG: control group, IG: intervention group, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure*Significant association. Changes from baseline in the anthropometric and biochemical parameters in the CG and IG using the paired t-test (mean ± SD) (n = 145). CG: control group, IG: intervention group, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High Density Lipoprotein Cholesterol, LDL-C: Low Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure *Significant association. Fig. 1Mean difference from baseline to 3 months within the two arms (n = 145). *Significant difference. CG: Control Group, IG: Intervention Group, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure Mean difference from baseline to 3 months within the two arms (n = 145). *Significant difference. CG: Control Group, IG: Intervention Group, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure Analysis of co-variance (ANCOVA) results of different MetS components According to the ANCOVA test results, the intervention (TLC) led to significant reductions in body weight, WC, BMI, TC, FBG, TG, and SBP. On average over time, participants in the IG had a 0.868 kg (95% CI: − 1.360, − 0.377) lower mean body weight compared to the CG, indicating that the intervention accounted for 7.9% of the variation in body weight from baseline. Similarly, WC decreased by a mean of 1.65 cm (95% CI: − 2.46, − 0.83), with the intervention explaining 10.1% of its variation, while BMI was reduced by 0.36 kg/m2 (95% CI: − 0.55, − 0.17), accounting for 8.8% of the variation due to the intervention. Significant decreases were also observed in biochemical parameters. Compared with the CG, the IG showed lower mean levels of TC by 5.51 mg/dL (95% CI: − 10.17, − 0.85), FBG by 4.83 mg/dL (95% CI: − 7.29, − 2.37), and TG by 5.87 mg/dL (95% CI: − 11.57, − 0.17). After adjusting for baseline differences, the intervention explained 3.7%, 9.6%, and 2.8% of the variation in TC, FBG, and TG, respectively. Furthermore, SBP decreased by an average of 4.76 mmHg, with the intervention accounting for 7.4% of its variation. The mean number of MetS components was also significantly reduced by 0.424 (95% CI: − 0.687, − 0.160) in the IG compared with the CG, with 6.6% of the variation attributable to the intervention (Table 5; Fig. 2). Fig. 2Adjusted mean difference of the continuous outcome variables from ANCOVA (n = 145). WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. Adjusted mean difference of the continuous outcome variables from ANCOVA (n = 145). WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. Table 5ANCOVA test result of different metabolic and anthropometric components (n = 145).VariablesMean difference (95% CI)F-value (p-value)Partial Eta squaredWeight-0.868 (-1.360,-0.377)12.192 (0.001)*0.079WC-1.65 (-2.46,-0.83)15.871 (< 0.001)*0.101BMI-0.36 (-0.55,-0.17)13.719 (< 0.001)*0.088TC-5.51 (-10.17,-0.85)5.473 (0.021)*0.037FBG-4.83 (-7.29,-2.37)15.113 (< 0.001)*0.096TG-5.87 (-11.57,-0.17)4.142 (0.044)*0.028HDL-C2.00 (-0.16,4.16)3.337 (0.070)0.023LDL-C-3.12 (-6.41,0.18)3.502 (0.063)0.024SBP-4.76 (-7.55,-1.97)11.400 (0.001)*0.074DBP-1.51 (-3.28,0.27)2.822 (0.095)0.019No_ of MetS components-0.424 (-0.687,-0.160)10.094 (0.002)*0.066CI: Confidence Interval, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. Table 5ANCOVA test result of different metabolic and anthropometric components (n = 145).VariablesMean difference (95% CI)F-value (p-value)Partial Eta squaredWeight-0.868 (-1.360,-0.377)12.192 (0.001)*0.079WC-1.65 (-2.46,-0.83)15.871 (< 0.001)*0.101BMI-0.36 (-0.55,-0.17)13.719 (< 0.001)*0.088TC-5.51 (-10.17,-0.85)5.473 (0.021)*0.037FBG-4.83 (-7.29,-2.37)15.113 (< 0.001)*0.096TG-5.87 (-11.57,-0.17)4.142 (0.044)*0.028HDL-C2.00 (-0.16,4.16)3.337 (0.070)0.023LDL-C-3.12 (-6.41,0.18)3.502 (0.063)0.024SBP-4.76 (-7.55,-1.97)11.400 (0.001)*0.074DBP-1.51 (-3.28,0.27)2.822 (0.095)0.019No_ of MetS components-0.424 (-0.687,-0.160)10.094 (0.002)*0.066CI: Confidence Interval, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. ANCOVA test result of different metabolic and anthropometric components (n = 145). CI: Confidence Interval, WC: Waist Circumference, BMI: Body Mass Index, TC: Total Cholesterol, FBG: Fasting Blood Glucose, TG: Triglyceride, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. Discussion In this three-month interventional study, intensive TLC produced clinically meaningful reductions in key anthropometric and cardio-metabolic parameters among individuals with MetS. Compared to the CG, the IG showed significantly greater improvements in body weight, WC, BMI, and related metabolic risk markers. Over time, the IG exhibited an average reduction in body weight of 868 g, a 1.65 cm decrease in WC, and a 0.36 kg/m² reduction in BMI relative to the CG, accounting for 7.9%, 10.1%, and 8.8% of the observed variation attributable to the intervention, respectively. These findings indicate that short-term, structured TLC interventions can promote weight loss and improve anthropometric indicators, thereby potentially lowering overall cardio-metabolic risk. Consistent results have been reported in several interventional trials showing favorable anthropometric outcomes in the IG compared with the CG. Reported improvements include weight loss of 1.5–3.2 kg19,25–28, WC reductions of 2.3–4.1 cm19,26–30, and BMI decreases of 0.6–1.2 kg/m²30,31. Some studies found that WC increased in the CG but remained stable in the IG32, while short-term interventions (4–8 weeks) generally showed modest but significant reductions in body weight and WC27,33. Longer trials, such as a six-month study in Taiwan, further demonstrated improvements in BMI (–1.2 kg/m²) in the IG only31. Weight loss and reduced WC contribute to a decrease in visceral fat. Since abdominal obesity is a core component of MetS, and visceral adipose tissue plays a crucial role in lipid and glucose metabolism34, reductions in anthropometric parameters are expected to improve lipid profiles and enhance insulin sensitivity. This study also showed that individuals with MetS experienced significant metabolic improvements after the three-month TLC intervention. Compared to the CG, the IG had significantly lower TC, FBG, TG, and SBP. On average, TC was 5.51 mg/dL lower in the IG, accounting for 3.7% of the variation attributable to the intervention. Consistent results were observed in earlier studies25,26,35,36. A six-month trial in the Czech Republic reported significant decreases in TC (-7.3 mg/dL) at six weeks post-intervention in the IG36. Similarly, the IG demonstrated a 4.83 mg/dL lower FBG compared with the CG, explaining 9.6% of the variation attributed to the intervention. Comparable findings were observed in previous interventional studies25,26,28. A 12-week lifestyle intervention reduced FBG by − 6.2 mg/dL in the IG versus − 2.1 mg/dL in the CG26, while a six-month trial observed a mean reduction of − 7.8 mg/dL from baseline in the IG27. Similarly, another study found a 5.5% decline in FBG following a community-based intervention29. In a short-term (4-week) program, both groups exhibited significant decreases in FBG from baseline, with a slightly greater reduction in the IG (–4.1 mg/dL) than in the CG (–2.8 mg/dL)33. In contrast, one interventional trial reported no statistically significant difference in FBG between the groups29. In the present trial, the IG exhibited, on average, a 5.87 mg/dL lower TG level than the CG, accounting for 2.8% of the variation explained by the intervention. Similar findings were observed in earlier interventional studies28,32,33. A community-based lifestyle intervention resulted in a mean TG reduction of − 9.4 mg/dL in the IG compared to − 3.1 mg/dL in the CG29. Likewise, a six-month study reported significant declines in TG (–12.7 mg/dL) following nurse-led monthly counseling compared to standard primary care33. Another short-term (4-week) trial also demonstrated a TG reduction of − 8.2 mg/dL in the IG versus − 2.4 mg/dL in the CG34. In contrast, other studies reported no significant changes in TG between groups25,29. For blood pressure, the IG exhibited an average SBP reduction of 4.35 mmHg compared to the CG, explaining 7.4% of the variation attributable to the intervention effect. Similar findings have been reported in previous interventional studies26,29,30. A six-month trial in Italy showed a greater SBP reduction in the IG (–6.4 mmHg) than in the CG, likely due to the longer intervention period26. Likewise, other studies have documented modest yet significant SBP decreases ranging from − 3.5 to − 6.0 mmHg following lifestyle modification30,31, although one study reported no significant difference between groups32. No significant differences were observed in HDL-C, LDL-C, or DBP between the groups. The CG had higher baseline values than the IG, which may have led to relatively greater improvement in the CG due to the regression-to-the-mean effect—a likely explanation for the non-significant changes observed18. Similar non-significant results for HDL-C25 and DBP32 have been reported previously. However, other interventional studies demonstrated significant reductions in DBP ranging from − 3.8 to − 5.6 mmHg26,29. Contrasting findings were also noted in several studies, where HDL-C levels significantly increased by 4–8%28,29,33,37 and LDL-C levels significantly decreased by 6–10%25,33 from baseline in both groups. The proportion of participants with MetS decreased by 41.1% in the IG compared with a 15.3% reduction in the CG, indicating a substantial intervention effect. The likelihood of MetS resolution was approximately 3.9 times higher in the IG. Comparable reductions in MetS prevalence have been reported elsewhere. A six-month Italian study reported a 59% decrease in MetS prevalence in the IG, with no significant change in the CG26. In contrast, a six-month study observed only a modest, non-significant difference between groups (65.3% vs. 62.3%)27. A 12-month Saudi Arabian trial reported significant reductions in MetS prevalence only with intensive lifestyle modification (26.0%) and lifestyle plus metformin (22.4%)38. Likewise, shorter interventions showed meaningful benefits—a three-month study reduced MetS prevalence to 45.5% in the IG versus 69.7% in the CG19, and another reported MetS resolution in 64% of participants39. In the present study, the mean number of MetS components decreased by 0.424 in the IG compared with the CG, accounting for 6.6% of the variation, consistent with previous findings38,40. Clinical and epidemiological studies have consistently shown that MetS often begins with central obesity, which serves as a primary driver of the syndrome due to its strong association with multiple metabolic risk factors. The significant reduction in WC observed in this trial reinforces this relationship, as abdominal fat reduction likely contributed to improvements in TG and FBG levels through decreased insulin resistance. Insulin resistance, another key feature of MetS, promotes hyperglycemia and is largely driven by elevated circulating fatty acids derived from TG stored in adipose tissue. Therefore, reductions in both WC and TG indicate a favorable shift in metabolic regulation. This community-based, three-month TLC program demonstrated meaningful improvements in anthropometric and cardio-metabolic parameters and significantly reduced the prevalence of MetS. The intervention group achieved nearly four times higher odds of MetS resolution, confirming the effectiveness of TLC as a first-line, non-pharmacologic strategy emphasizing dietary modification, physical activity, and behavioral change. These findings affirm that even short-term, structured TLC interventions can produce substantial health benefits and are feasible, scalable, and cost-effective in community and primary healthcare settings. Weight loss and increased physical activity are well-documented to improve nearly all aspects of MetS41, and the present trial provides further empirical support for their role in reducing metabolic risk factors. In contrast to previous studies that involved smaller samples19,26,30–33,37,39,42, shorter duration27,43, single-component interventions such as exercise only programs40,44,45, telephone-based counseling19, concurrent drug use32, or single-gender populations27,33, this study implemented a comprehensive, three-month TLC program without pharmacologic treatment. Variability in outcomes across interventional studies may stem from differences in intervention duration, participant age, baseline health status, sample size, ethnicity, socioeconomic conditions, medication use, and eligibility criteria. Moreover, when participants are on concurrent drug therapy, observed improvements may not be entirely attributable to lifestyle interventions. Differences in statistical analysis methods also contribute to inconsistencies, as many studies have reported only within-group changes without adjusting for baseline differences, potentially leading to overestimated effects. These considerations underscore the importance of standardized, long-term, and well-controlled trials to more accurately assess the true impact of lifestyle interventions on MetS prevention and management. A notable strength of the trial was its low dropout rate and high adherence to follow-up counseling sessions, reflecting strong participant engagement. As a limitation, despite the statistically significant improvements observed, the magnitude of changes was small, likely due to the relatively short duration of the intervention. Conclusions This three-month community-based trial demonstrated that intensive TLC significantly improved anthropometric and cardio-metabolic parameters in individuals with MetS. The IG achieved statistically significant reductions in body weight, WC, BMI, TC, FBG, TG, and SBP compared with the CG, and showed nearly four times higher odds of MetS resolution. These findings indicate that even short-term, structured lifestyle interventions can effectively reduce metabolic risk factors and lower MetS prevalence by targeting key pathophysiologic mechanisms. The results underscore the importance of early implementation of TLC to achieve better outcomes, sustain health benefits, and reduce long-term healthcare costs. Given its practicality, scalability, and cost-effectiveness, intensive TLC should be integrated into community and primary healthcare services as a first-line strategy for the prevention and management of MetS. Overall, this study provides compelling evidence supporting the use of community-based lifestyle programs to improve metabolic health, fill gaps in current research, and offer a practical framework for public health action. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1